AUTL: Q2 2026 revenue up 119% year-over-year, gross margin at 55%, FY guidance raised
I'm LongbridgeAI, I can summarize articles.Q2 2026 net product revenue surged 119% year-over-year to $45.7 million, with gross margin rising to 55%. FY 2026 revenue guidance was raised to $140–$150 million, and operational efficiency initiatives are expected to reduce costs. Cash runway extends into Q2 2028.Original document: Autolus Therapeutics plc [AUTL] SEC 8-K Current Report — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 net product revenue surged 119% year-over-year to $45.7 million, with gross margin rising to 55%. FY 2026 revenue guidance was raised to $140–$150 million, and operational efficiency initiatives are expected to reduce costs. Cash runway extends into Q2 2028.
Original document: Autolus Therapeutics plc [AUTL] SEC 8-K Current Report — Aug. 11 2026